Search Results - "SHAFMAN, Timothy D"

Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma by Kann, Benjamin H., Verma, Vivek, Stahl, John M., Ross, Rudi, Dosoretz, Arie P., Shafman, Timothy D., Gross, Cary P., Park, Henry S., Yu, James B., Decker, Roy H.

“…•SBRT remains controversial for operable early-stage NSCLC.•This study analyzes a cohort of >400 operable patients treated with SBRT.•Disease control outcomes…”
Get full text

Current status of immunotherapy and gene therapy for high-grade gliomas by Marsh, James C, Goldfarb, Justin, Shafman, Timothy D, Diaz, Aidnag Z

“…Despite improvements in surgical technique, radiation therapy delivery, and options for systemic cytotoxic therapy, the median survival for patients with newly…”
Get more information

Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents by Kharbanda, Surender, Ren, Ruibao, Pandey, Pramod, Shafman, Timothy D, Feller, Stephen M, Weichselbaum, Ralph R, Kufe, Donald W

“…THE product of the c-abl gene is a non-receptor tyrosine kinase that is localized to the nucleus and cytoplasm. The precise function of c-Abl is unknown. Here…”
Get full text

Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury by Lind, Pehr A, Marks, Lawrence B, Hollis, Donna, Fan, Ming, Zhou, Su-Min, Munley, Michael T, Shafman, Timothy D, Jaszczak, Ronald J, Coleman, R Edward

“…To assess the utility of dosimetric/functional metrics as predictors of symptomatic radiation pneumonitis using receiver operating characteristic curves…”
Get more information

Phase I Trial Results of Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas by COKGOR, Ilkcan, AKABANI, Gamal, PEGRAM, Charles N, WIKSTRAND, Carol J, SHAFMAN, Timothy D, HERNDON, James E, PROVENZALE, James M, ZALUTSKY, Michael R, BIGNER, Darell D, KUAN, Chien-Tsun, FRIEDMAN, Henry S, FRIEDMAN, Allan H, COLEMAN, R. Edward, MCLENDON, Roger E, BIGNER, Sandra H, ZHAO, Xiao-Guang, GARCIA-TURNER, Ana M

“…To determine the maximum-tolerated dose (MTD) of iodine-131 ((131)I)-labeled 81C6 antitenascin monoclonal antibody (mAb) administered clinically into…”
Get full text

Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model by Gao, Sarah J, Jin, Lan, Meadows, Hugh W, Shafman, Timothy D, Gross, Cary P, Yu, James B, Aerts, Hugo J W L, Miccio, Joseph A, Stahl, John M, Mak, Raymond H, Decker, Roy H, Kann, Benjamin H

“…Distant metastases (DMs) are the primary driver of mortality for patients with early stage NSCLC receiving stereotactic body radiation therapy (SBRT), yet…”
Get more information

Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis by Kann, Benjamin H., Miccio, Joseph A., Stahl, John M., Ross, Rudi, Verma, Vivek, Dosoretz, Arie P., Park, Henry S., Shafman, Timothy D., Gross, Cary P., Yu, James B., Decker, Roy H.

“…•Systemic therapy is rarely used in early stage lung cancer treated with radiation.•Patients who receive adjuvant systemic therapy have fewer regional-distant…”
Get full text

The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy by Stahl, John M., Ross, Rudi, Harder, Eileen M., Mancini, Brandon R., Soulos, Pamela R., Finkelstein, Steven E., Shafman, Timothy D., Dosoretz, Arie P., Evans, Suzanne B., Husain, Zain A., Yu, James B., Gross, Cary P., Decker, Roy H.

“…To determine the effect of biologically effective dose (BED10) and radiation treatment schedule on overall survival (OS) in patients with early-stage non-small…”
Get full text

Using Plasma Transforming Growth Factor Beta-1 During Radiotherapy to Select Patients for Dose Escalation by ANSCHER, Mitchell S, MARKS, Lawrence B, JIRTLE, Randy L, SHAFMAN, Timothy D, CLOUGH, Robert, HONG HUANG, TISCH, Andrea, MUNLEY, Michael, HERNDON, James E, GARST, Jennifer, CRAWFORD, Jeffrey

“…The ability to prescribe treatment based on relative risks for normal tissue injury has important implications for oncologists. In non-small-cell lung cancer,…”
Get full text

Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer by Johnson, Skyler Bryce, Soulos, Pamela R, Shafman, Timothy D, Mantz, Constantine A, Dosoretz, Arie P, Ross, Rudi, Finkelstein, Steven E, Collins, Sean P, Suy, Simeng, Brower, Jeffrey V, Ritter, Mark A, King, Christopher R, Kupelian, Patrick A, Horwitz, Eric M, Pollack, Alan, Abramowitz, Matthew C, Hallman, Mark A, Faria, Sergio, Gross, Cary P, Yu, James B

“…Abstract Background and purpose Evaluate changes in bowel, urinary and sexual patient-reported quality of life following treatment with moderately…”
Get full text

Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer by Hernando, M L, Marks, L B, Bentel, G C, Zhou, S M, Hollis, D, Das, S K, Fan, M, Munley, M T, Shafman, T D, Anscher, M S, Lind, P A

“…To relate lung dose-volume histogram-based factors to symptomatic radiation pneumonitis (RP) in patients with lung cancer undergoing 3-dimensional (3D)…”
Get more information

Dosimetric and clinical predictors for radiation-induced esophageal injury by Ahn, Sung-Ja, Kahn, Daniel, Zhou, Sumin, Yu, Xiaoli, Hollis, Donna, Shafman, Timothy D, Marks, Lawrence B

“…To evaluate the clinical and three-dimensional dosimetric parameters associated with esophageal injury after radiotherapy (RT) for non-small-cell lung cancer…”
Get more information

Challenges in defining radiation pneumonitis in patients with lung cancer by Kocak, Zafer, Evans, Elizabeth S, Zhou, Su-Min, Miller, Keith L, Folz, Rodney J, Shafman, Timothy D, Marks, Lawrence B

“…To assess the difficulty of assigning a definitive clinical diagnosis of radiation (RT)-induced lung injury in patients irradiated for lung cancer. Between…”
Get more information

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas by Reardon, David A, Akabani, Gamal, Coleman, R Edward, Friedman, Allan H, Friedman, Henry S, Herndon, 2nd, James E, Cokgor, Ilkcan, McLendon, Roger E, Pegram, Charles N, Provenzale, James M, Quinn, Jennifer A, Rich, Jeremy N, Regalado, Lorna V, Sampson, John H, Shafman, Timothy D, Wikstrand, Carol J, Wong, Terence Z, Zhao, Xiao-Guang, Zalutsky, Michael R, Bigner, Darell D

“…To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate…”
Get full text

Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? by Miller, Keith L, Shafman, Timothy D, Anscher, Mitchell S, Zhou, Su-Min, Clough, Robert W, Garst, Jennifer L, Crawford, Jeffrey, Rosenman, Julian, Socinski, Mark A, Blackstock, William, Sibley, Gregory S, Marks, Lawrence B

“…To assess the incidence of clinically significant bronchial stenosis in patients treated with high doses (i.e., >70 Gy) of twice-daily external beam radiation…”
Get more information

"Anatomically-correct" dosimetric parameters may be better predictors for esophageal toxicity than are traditional CT-based metrics by Kahn, Daniel, Zhou, Sumin, Ahn, Sung-Ja, Hollis, Donna, Yu, Xiaoli, D'Amico, Thomas A, Shafman, Timothy D, Marks, Lawrence B

“…Incidental esophageal irradiation during lung cancer therapy often causes morbidity. There is interest in trying to relate esophageal dosimetric parameters to…”
Get more information

Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer by Miller, Keith L, Marks, Lawrence B, Sibley, Gregory S, Clough, Robert W, Garst, Jennifer L, Crawford, Jeffrey, Shafman, Timothy D

“…To review the outcome of patients with limited-stage small-cell lung cancer receiving daily thoracic irradiation (RT) to approximately 60 Gy. The records of…”
Get more information

Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury by Anscher, Mitchell S, Garst, Jennifer, Marks, Lawrence B, Larrier, Nicole, Dunphy, Frank, Herndon, 2nd, James E, Clough, Robert, Marino, Christine, Vujaskovic, Zeljko, Zhou, Sumin, Dewhirst, Mark W, Shafman, Timothy D, Crawford, Jeffrey

“…Thalidomide has broad anticytokine properties, which might protect normal tissues in patients undergoing chemoradiotherapy. The purpose of this study was to…”
Get more information

Relating radiation-induced regional lung injury to changes in pulmonary function tests by Fan, M, Marks, L B, Lind, P, Hollis, D, Woel, R T, Bentel, G G, Anscher, M S, Shafman, T D, Coleman, R E, Jaszczak, R J, Munley, M T

“…To determine whether the sum of radiotherapy (RT)-induced reductions in regional lung perfusion is quantitatively related to changes in global lung function as…”
Get more information

A practical approach to pulmonary risk assessment in the radiotherapy of lung cancer by Miller, Keith L., Shafman, Timothy D., Marks, Lawrence B.

“…The risk of lung injury is a significant limiting factor in the use of thoracic radiotherapy for lung cancer. Given the high mortality and local failure rates…”
Get full text